ViroMissile Clears First Dose Cohort in Phase I Cancer Virus Trial
Safety reviewers approved dose escalation in ViroMissile's first-in-human trial of its intravenously delivered oncolytic virus therapy for solid tumors.
ViroMissile, Inc. announced Wednesday that an independent Safety Review Committee has cleared its Phase I clinical trial of IDOV-2 to advance to a higher dose cohort after completing enrollment and safety review of the first group of patients, marking an early but significant milestone for the San Diego-based cancer immunotherapy company.
IDOV-2, formerly known as IDOV-Immune, is part of ViroMissile's proprietary IDOV platform — shorthand for Intravenously Deliverable Oncolytic Virus — a technology designed to deliver virus-based cancer-fighting agents directly through the bloodstream rather than by injection into tumors. The first-in-human study, registered under clinical trial identifier NCT06910657, is enrolling patients diagnosed with advanced solid tumors.
Read more Broadridge Nominates Srinivas Tallapragada to Board of Directors →
The trial is being conducted across two countries, with sites operating in the United States and in Australia through ViroMissile's subsidiary, ViroMissile Australia, PTY, LTD. The international scope of the study reflects an increasingly common strategy among smaller biotech firms seeking to accelerate patient enrollment by accessing clinical infrastructure in multiple regulatory jurisdictions.
Safety Review Committees in Phase I oncology trials are convened specifically to evaluate adverse event data at each dose level before authorizing escalation, functioning as an independent check on participant safety throughout the dose-finding process. Clearance from such a body to proceed does not constitute evidence of efficacy but signals that the initial dose was tolerated without disqualifying safety signals.
The completion of the first cohort positions ViroMissile among a broader wave of biotech developers pursuing oncolytic virus platforms, which have attracted growing scientific and investor interest as a complement to checkpoint inhibitor and cell therapy approaches in oncology. Continue reading at GlobeNewswire - Industry News on Financial Services.
